Skip to main content
. Author manuscript; available in PMC: 2012 Jul 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2011 Mar 4;38(7):1335–1343. doi: 10.1007/s00259-011-1765-5

Fig. 1.

Fig. 1

In vitro investigation of DOTA-TRC105. a Flow cytometry analysis of TRC105 and DOTA-TRC105 in HUVECs (CD105-positive) and MCF-7 (CD105-negative) cells at different concentrations. b Fluorescence microscopy images of HUVECs using either TRC105 or DOTA-TRC105 (2 μg/mL) as the primary antibody. Various control images are also shown.